Related references
Note: Only part of the references are listed.Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier
Cecilia Carpio et al.
BLOOD (2020)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study
Jean-Marie Michot et al.
LANCET HAEMATOLOGY (2020)
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity
Jiye Liu et al.
LEUKEMIA (2019)
PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice
Julia Weber et al.
NATURE COMMUNICATIONS (2019)
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Yang Liu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Drew W. Rasco et al.
CLINICAL CANCER RESEARCH (2019)
Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma
Ajinkya Patil et al.
BLOOD ADVANCES (2019)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity
Quinlan L. Sievers et al.
BLOOD (2018)
UBE2G1 governs the destruction of cereblon neomorphic substrates
Gang Lu et al.
ELIFE (2018)
Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling
Markus Brockmann et al.
NATURE (2017)
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
Jian An et al.
NATURE COMMUNICATIONS (2017)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL
Patrick R. Hagner et al.
BLOOD (2015)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression
Baochun Zhang et al.
CELL REPORTS (2015)
AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation
Valentina Cianfanelli et al.
NATURE CELL BIOLOGY (2015)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
KCTD5, a putative substrate adaptor for cullin3 ubiquitin ligases
Yolanda Bayon et al.
FEBS JOURNAL (2008)
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling
Sivakumar Vallabhapurapu et al.
NATURE IMMUNOLOGY (2008)
Ambra1 regulates autophagy and development of the nervous system
Gian Maria Fimia et al.
NATURE (2007)
The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
A Kovalenko et al.
NATURE (2003)